Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 7/20 | 0.47 |
| ▸ | PLK1 | P53350 | 4/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280279 | 0.88 | SLC16A3 (0.55) | SLC16A3PLK1PLK3SMN1; SMN2F2R | |
| Methylamine SCHEMBL27566541 | 0.84 | SMN1; SMN2 (0.52) | SLC16A3PLK1PLK3GRM5SMN1; SMN2 | |
| SCHEMBL14280281 | 0.84 | SMN1; SMN2 (0.54) | SLC16A3PLK1PLK3GRM5SMN1; SMN2 | |
| N-Phenylbenzamide SCHEMBL4874327 | 0.82 | KCNK3 (0.57) | SLC16A3PLK1PLK3F2R | |
| SCHEMBL4671630 | 0.73 | SMN1; SMN2 (0.54) | SLC16A3GRM5SMN1; SMN2F2RALDH1A1 | |
| SCHEMBL4831437 | 0.72 | SLC16A3 (0.60) | SLC16A3PLK1PLK3 | |
| SCHEMBL28339940 | 0.72 | MEN1 (0.52) | BCAT2 | |
| SCHEMBL12893297 | 0.72 | SMN1; SMN2 (0.53) | SLC16A3GRM5SMN1; SMN2F2RALDH1A1 | |
| SCHEMBL13645650 | 0.72 | SMN1; SMN2 (0.56) | HTTGRM5SMN1; SMN2F2RALDH1A1 | |
| SCHEMBL10943427 | 0.72 | SMN1; SMN2 (0.53) | SLC16A3HTTGRM5SMN1; SMN2F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314958-B2 | Phenylbenzamides | BAYER CROPSCIENCE AG (DE) | 2008-01-01 | — | — | US | disclosed |
| US-20060211771-A1 | Phenyl benzamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-09-21 | — | — | US | disclosed |
| EP-1519913-A1 | PHENYL BENZAMIDES | Bayer CropScience AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005242-A1 | PHENYL BENZAMIDES | BAYER CROPSCIENCE AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211771-A1 | Phenyl benzamides | PADI1, PNMT, BRPF3 | SLC16A3 4753/4885PLK1 4215/4885PLK3 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.